AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30962877 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual plus manual therapy (5 sessions, 30 min each)
Number of subjects: 64
Study 30962877 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 64
Study 30962877 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual plus manual therapy
Number of subjects: 64
Study 29129455 — intervention group
Group type: COMPARATOR
Intervention: Type 2 Diabetes
Number of subjects: 0
Study 29129455 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial state
Number of subjects: 0
Study 29129455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting AC16:0
Number of subjects: 0
Study 26755593 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent inactivated influenza vaccine (ATIV)
Number of subjects: 90
Study 26755593 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 90
Study 23774008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for childhood OCD, 12-session course
Number of subjects: 40
Study 23774008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for childhood OCD
Number of subjects: 40
Study 22926289 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 25 mg/day
Number of subjects: 76
Study 22926289 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 25 mg/day plus tolterodine 2 mg (twice a day)
Number of subjects: 76
Study 22926289 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 2 mg (twice a day)
Number of subjects: 76
Study 20116107 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotional messages with more vocal information
Number of subjects: 0
Study 20116107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearful emotional messages
Number of subjects: 0
Study 20116107 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotional messages with intense vocal tone
Number of subjects: 0
Study 17661956 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi intervention (16-week program of community-based tai chi classes of 1 hour duration per week)
Number of subjects: 702
Study 17661956 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list control)
Number of subjects: 702
Study 17661956 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi intervention
Number of subjects: 702
Study 16238864 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief research-based leaflet-like intervention promoting fruit and vegetable consumption
Number of subjects: 0
Study 16238864 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12453954 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 216
Study 12453954 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 216
Study 12453954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 10521751 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning meal administered at 7 AM after a fast of ≥5 hours
Number of subjects: 30
Study 10521751 — intervention group
Group type: COMPARATOR
Intervention: Evening meal administered at 9 PM after a fast of ≥5 hours
Number of subjects: 30
Study 10521751 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning meal
Number of subjects: 30
Study 10521751 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patients
Number of subjects: 30
Study 8729258 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental product based on raw wheat flour subjected to enzymatic hydrolysis
Number of subjects: 35
Study 8729258 — intervention group
Group type: COMPARATOR
Intervention: Control product based on extruded flours and milk protein
Number of subjects: 35
Study 8729258 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental product
Number of subjects: 35
Study 8729258 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 35
Study 1906413 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms/day)
Number of subjects: 1000
Study 1906413 — intervention group
Group type: COMPARATOR
Intervention: No prevention (control)
Number of subjects: 1000
Study 7195642 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid (AMCA)
Number of subjects: 41
Study 7195642 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study 31022892 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron folate group (60 mg elemental iron and folate)
Number of subjects: 402
Study 31022892 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron, vitamin A and folate group
Number of subjects: 402
Study 31022892 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A group (15,000 IU of vitamin)
Number of subjects: 402
Study 31022892 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate group (2.5 mg of folate)
Number of subjects: 402
Study 31022892 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 402
Study 30267399 — intervention group
Group type: EXPERIMENTAL
Intervention: 153 Sm-EDTMP
Number of subjects: 50
Study 30267399 — intervention group
Group type: EXPERIMENTAL
Intervention: 177 Lu-EDTMP
Number of subjects: 50
Study 26914455 — intervention group
Group type: EXPERIMENTAL
Intervention: Veratric acid (VA) cream applied topically; specific dosage and duration not mentioned.
Number of subjects: 0
Study 26914455 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; no control intervention mentioned.
Number of subjects: 0
Study 25200338 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation set
Number of subjects: 3413
Study 25200338 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation set
Number of subjects: 3413
Study 22706571 — intervention group
Group type: COMPARATOR
Intervention: IV iron sucrose (IS)
Number of subjects: 13
Study 22706571 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron sucrose co-administered with IV Vitamin C (IS + C)
Number of subjects: 13
Study 20130877 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin (75 mg/m2 every 3 weeks)
Number of subjects: 147
Study 20130877 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and cisplatin with radiation therapy (RT; 45 Gy)
Number of subjects: 147
Study 20130877 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin (arm A)
Number of subjects: 147
Study 20130877 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and cisplatin with RT (arm B)
Number of subjects: 147
Study 20130877 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC1 positive tumors
Number of subjects: 147
Study 18040014 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at a mean dose of 2000 mg/day
Number of subjects: 28
Study 18040014 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) at a mean dose of 564 mg/day
Number of subjects: 28
Study 18040014 — intervention group
Group type: COMPARATOR
Intervention: Non-drug
Number of subjects: 28
Study 15656813 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily use of topical corticosteroids
Number of subjects: 10
Study 15656813 — intervention group
Group type: COMPARATOR
Intervention: More frequent use of topical corticosteroids
Number of subjects: 10
Study 15656813 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily treatment with potent topical corticosteroids
Number of subjects: 10
Study 15656813 — intervention group
Group type: EXPERIMENTAL
Intervention: Three times daily use of very potent topical corticosteroids
Number of subjects: 10
Study 12198015 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber, low fat meal
Number of subjects: 15
Study 12198015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fiber, high fat meal
Number of subjects: 15
Study 12198015 — intervention group
Group type: COMPARATOR
Intervention: Low fiber, low fat meal
Number of subjects: 15
Study 12198015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, low-fiber meal
Number of subjects: 15
Study 12198015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fiber, low-fat meal
Number of subjects: 15
Study 10608543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) (Pentaspan)
Number of subjects: 45
Study 10608543 — intervention group
Group type: COMPARATOR
Intervention: Gelatine (Gelofusine)
Number of subjects: 45
Study 7491877 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (30 mg)
Number of subjects: 144
Study 7491877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg)
Number of subjects: 144
Study 7491877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 1851068 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline skin microcirculation (laser Doppler flux)
Number of subjects: 24
Study 1851068 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma noradrenaline concentration
Number of subjects: 24
Study 1851068 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 2‐adrenoceptor density
Number of subjects: 24
Study 1851068 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 2‐adrenoceptor density/beta 2‐adrenoceptor density ratio
Number of subjects: 24
Study 1851068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic test
Number of subjects: 24
Study 1851068 — intervention group
Group type: COMPARATOR
Intervention: Finger-cooling test
Number of subjects: 24
Study 6809627 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Number of subjects: 64
Study 6809627 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Number of subjects: 64
Study 6809627 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Number of subjects: 64
Study 6809627 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Number of subjects: 64
Study 6809627 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms in a 20-microliter/microgram volume
Number of subjects: 64
Study 6809627 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting serum bactericidal activity (greater than 4 log2)
Number of subjects: 64
Study 6809627 — intervention group
Group type: EXPERIMENTAL
Intervention: High preexisting serum bactericidal titers
Number of subjects: 64
Study 31571526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic treatment regimen for increasing motivation to attend treatments
Number of subjects: 0
Study 31571526 — intervention group
Group type: COMPARATOR
Intervention: Standard two-arm randomized trial
Number of subjects: 0
Study 29523170 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular feedback about activity levels via Smart watch
Number of subjects: 0
Study 29523170 — intervention group
Group type: COMPARATOR
Intervention: No feedback while wearing the Smart watch
Number of subjects: 0
Study 26291817 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg intravaginal progesterone
Number of subjects: 200
Study 26291817 — intervention group
Group type: COMPARATOR
Intervention: 600 mg intravaginal progesterone
Number of subjects: 200
Study 25261353 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Group
Number of subjects: 0
Study 25261353 — intervention group
Group type: COMPARATOR
Intervention: Definite Group
Number of subjects: 0
Study 25261353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 21836549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with enhanced support for maternal-infant bonding, including information about newborn behaviors and encouragement for skin-to-skin contact.
Number of subjects: 0
Study 21836549 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving weekly encouragement to remain smoke free and routine breastfeeding support.
Number of subjects: 0
Study 21836549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with enhanced support for maternal-infant bonding.
Number of subjects: 0
Study 21162922 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injection of ropivacaine, morphine and epinephrine
Number of subjects: 36
Study 21162922 — intervention group
Group type: COMPARATOR
Intervention: Patient‐controlled epidural analgesia (PCEA)
Number of subjects: 36
Study 17923867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive CEP (C 1800 mg m(‐2), E 50 mg m(‐2), P 75 mg m(‐2) with filgrastim 5 mug kg(‐1) per day x 10 days)
Number of subjects: 164
Study 17923867 — intervention group
Group type: COMPARATOR
Intervention: Standard CEP (C 500 mg m(‐2), E 50 mg m(‐2), P 75 mg m(‐2))
Number of subjects: 164
Study 15716329 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg)
Number of subjects: 35
Study 15716329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 12496748 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 6%
Number of subjects: 20
Study 12496748 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1%
Number of subjects: 20
Study 12496748 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 6% and 1%
Number of subjects: 20
Study 9818309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cambridge Contextual Reading Test (CCRT)
Number of subjects: 21
Study 9818309 — intervention group
Group type: EXPERIMENTAL
Intervention: National Adult Reading Test (NART)
Number of subjects: 21
Study 9818309 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot‐the‐Word Test (STW)
Number of subjects: 21
Study 9818309 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 21
Study 7516001 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 20
Study 7516001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2913893 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 6-min treadmill run (S1A)
Number of subjects: 7
Study 2913893 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 6-min treadmill run (S2A)
Number of subjects: 7
Study 2913893 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min treadmill run at a lower gradient (W1B)
Number of subjects: 7
Study 2913893 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 6-min treadmill run (S2B)
Number of subjects: 7
Study 29706210 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (antibiotic prophylaxis)
Number of subjects: 38
Study 29706210 — intervention group
Group type: COMPARATOR
Intervention: Glucose (placebo control)
Number of subjects: 38
Study 27472560 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP (web-based intervention promoting healthy eating, physical activity, and social connections)
Number of subjects: 75
Study 27472560 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 75
Study 27472560 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP (web-based intervention)
Number of subjects: 75
Study 24666802 — intervention group
Group type: EXPERIMENTAL
Intervention: Website
Number of subjects: 40
Study 24666802 — intervention group
Group type: COMPARATOR
Intervention: Printed leaflet
Number of subjects: 40
Study 22898578 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit™ training
Number of subjects: 27
Study 20177681 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,000 IU/day low molecular weight heparin (LMWH) prophylaxis
Number of subjects: 60
Study 18267051 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 80/4.5 microg (160/9 microg)
Number of subjects: 480
Study 18267051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 18267051 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol DPI 4.5 microg (9 microg)
Number of subjects: 480
Study 16970101 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA), n = 23
Number of subjects: 46
Study 16970101 — intervention group
Group type: COMPARATOR
Intervention: Nimotop, n = 23
Number of subjects: 46
Study 12935823 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T levels >0.1 microg/L
Number of subjects: 7115
Study 12935823 — intervention group
Group type: COMPARATOR
Intervention: Troponin T levels <=0.1 microg/L
Number of subjects: 7115
Study 12935823 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T cutoff value 0.03 microg/L
Number of subjects: 7115
Study 12935823 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T cutoff value 0.01 microg/L
Number of subjects: 7115
Study 12935823 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T cutoff value <=0.01 microg/L
Number of subjects: 7115
Study 10673519 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (filgrastim) administered at a daily dose of 5 microg/kg after two courses of intensive consolidation chemotherapy (ICC)
Number of subjects: 194
Study 8790153 — intervention group
Group type: COMPARATOR
Intervention: Heparin-coated circuits (Duraflo II) and reduced systemic heparinization (ACT > 250s)
Number of subjects: 22
Study 8790153 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-coated circuits and standard heparin administration (ACT > 480s)
Number of subjects: 22
Study 7969680 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic treatment
Number of subjects: 28
Study 7969680 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor treatment
Number of subjects: 28
Study 7969680 — intervention group
Group type: EXPERIMENTAL
Intervention: 3H‐ANG(1‐8) infusion (0.5, 2.0, and 2.5 ng/kg/min)
Number of subjects: 28
Study 3593628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine administered immediately after a meal
Number of subjects: 12
Study 3593628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine administered 2 hours after a meal
Number of subjects: 12
Study 3593628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine administered 0.5 hours before a meal
Number of subjects: 12
Study 3593628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine administered 3 hours after a meal
Number of subjects: 12
Study 3593628 — intervention group
Group type: COMPARATOR
Intervention: Ibopamine administered in fasting state
Number of subjects: 12
Study 29768633 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech Recognition (SR)
Number of subjects: 35
Study 29768633 — intervention group
Group type: COMPARATOR
Intervention: Keyboard and Mouse (KBM)
Number of subjects: 35
Study 28131081 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g γ‐glutamylcysteine (γ‐GC)
Number of subjects: 14
Study 28131081 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g γ‐glutamylcysteine (γ‐GC)
Number of subjects: 14
Study 26775547 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG and PVI using intraoperative irrigated radiofrequency ablation (CABG+PVI)
Number of subjects: 95
Study 26775547 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG and MM procedure using intraoperative irrigated radiofrequency ablation (CABG+MM)
Number of subjects: 95
Study 26775547 — intervention group
Group type: COMPARATOR
Intervention: Isolated CABG (CABG alone)
Number of subjects: 95
Study 26775547 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG+PVI and CABG+MM
Number of subjects: 95
Study 23432964 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI <25 kg/m2 (normal weight)
Number of subjects: 5495
Study 23432964 — intervention group
Group type: COMPARATOR
Intervention: BMI >25 kg/m2 (overweight and obese)
Number of subjects: 5495
Study 21957976 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan-based plus simvastatin therapy
Number of subjects: 41
Study 21957976 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan-based monotherapy
Number of subjects: 41
Study 18781668 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT-MOMS)
Number of subjects: 22
Study 18781668 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 22
Study 18781668 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed mothers of healthy children
Number of subjects: 22
Study 16680067 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/MPA (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg)
Number of subjects: 519
Study 16680067 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA (17beta‐estradiol 2 mg plus norethisterone acetate 1 mg)
Number of subjects: 519
Study 16680067 — intervention group
Group type: EXPERIMENTAL
Intervention: Low E2/NETA (17beta‐estradiol 1 mg plus norethisterone acetate 0.5 mg)
Number of subjects: 519
Study 16680067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 519
Study 15238182 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional adjustment group
Number of subjects: 75
Study 15238182 — intervention group
Group type: COMPARATOR
Intervention: Target adjustment group
Number of subjects: 75
Study 11742965 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols for liberating patients from MV driven by nonphysician HCPs
Number of subjects: 0
Study 11742965 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial (SBT)
Number of subjects: 0
Study 11742965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator management strategies for patients failing SBT
Number of subjects: 0
Study 11742965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Number of subjects: 0
Study 11742965 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeating a trial of spontaneous breathing
Number of subjects: 0
Study 8764716 — intervention group
Group type: EXPERIMENTAL
Intervention: Banked cultured human epidermal allografts
Number of subjects: 20
Study 8764716 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 20
Study 1799474 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b 5 million units subcutaneously three times weekly until progression or relapse
Number of subjects: 19
Study 1799474 — intervention group
Group type: COMPARATOR
Intervention: Prednimustine and mitoxantrone (PmM) regimen
Number of subjects: 19
Study 1799474 — intervention group
Group type: COMPARATOR
Intervention: Historical comparison to unmaintained first remission
Number of subjects: 19